Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy
NCT01242917Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of CCX354 in rheumatoid arthritis (RA) (3 arms), sponsored by Amgen. Primary endpoint: Subject incidence of adverse events at 12 weeks. Started Sep 2010; status: completed.
02
Drugs
CCX354
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01242917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01242917.